Multiple sclerosis (MS) is a degenerative, chronic inflammatory disease of the central nervous system that leads to cumulative neurologic disability over several years. Although MS affects over 400,000 individuals in the United States and about 2.1 million individuals worldwide, its etiology and pathogenesis are largely unknown. Moreover, the progression, severity, and specific symptoms of MS are unpredictable and vary from one person to another. While individuals of all ages are affected by MS, it is more commonly diagnosed in young adults, particularly women, between the ages of 20 and 40. Currently, there is no cure for MS.
Since its inception in fiscal year 2009 (FY09) through FY12, the Multiple Sclerosis Research Program (MSRP) has invested over $18.1 million in supporting innovative and impactful research that addresses fundamental issues and gaps in MS. The mission of the MSRP is to identify and fund promising research projects that are relevant to the prevention, etiology, pathogenesis, assessment, and treatment of MS and to ultimately lessen its personal and societal impact.
Congressional Appropriations
- $14.3 million in FY09-11
- $3.8 million in FY12
Funding Summary
- 45 Awards in FY09-11
- Previous Applications Recommended for Funding
Integration Panels
